圣湘生物(688289) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 reached ¥390,946,762.39, representing a year-on-year increase of 100.31%[7] - The net profit attributable to shareholders for Q1 2024 was ¥81,024,703.84, reflecting a growth of 35.01% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥73,755,740.91, showing a significant increase of 1962.06% year-on-year[7] - Basic and diluted earnings per share for Q1 2024 were both ¥0.14, up by 35.01% from the previous year[10] - The total operating revenue for Q1 2024 was CNY 390,946,762.39, a significant increase from CNY 195,173,984.72 in Q1 2023, representing a growth of approximately 100%[33] - The net profit for Q1 2024 was CNY 73,410,291.06, up from CNY 59,989,487.46 in Q1 2023, reflecting a growth of approximately 22.4%[33] - The total comprehensive income for Q1 2024 was CNY 75,327,140.62, compared to CNY 57,895,465.33 in Q1 2023, indicating a growth of approximately 30%[37] Research and Development - Total R&D investment amounted to ¥63,925,944.05, an increase of 31.04% year-on-year, while R&D investment as a percentage of operating revenue decreased by 8.65 percentage points to 16.35%[10] - The research and development expenses for Q1 2024 were CNY 55,402,242.13, an increase from CNY 46,345,922.89 in Q1 2023, indicating a growth of about 19.4%[33] Assets and Liabilities - The company's total assets at the end of Q1 2024 were ¥8,745,537,379.34, a 3.45% increase from the end of the previous year[10] - Total assets increased to CNY 8,745,537,379.34, up from CNY 8,454,204,974.00, representing a growth of approximately 3.43%[24] - Total liabilities reached CNY 1,216,440,666.94, up from CNY 1,029,297,739.69, marking an increase of around 18.14%[25] - Owner's equity attributable to shareholders rose to CNY 7,309,254,390.45 from CNY 7,201,271,019.35, showing an increase of about 1.50%[25] Cash Flow - The net cash flow from operating activities for Q1 2024 was negative at -¥125,646,118.28, representing a decrease of 6.58% year-on-year[7] - The cash flow from operating activities in Q1 2024 was CNY 433,059,249.03, compared to CNY 444,322,502.96 in Q1 2023, indicating a slight decrease of around 2.5%[37] - Operating cash inflow totaled $460 million, a decrease from $567 million year-over-year[39] - Cash outflow from operating activities was $586 million, down from $685 million year-over-year[39] - Net cash flow from operating activities was -$126 million, compared to -$118 million in the previous year[39] - The company reported a net increase in cash and cash equivalents of $85 million, contrasting with a decrease of $670 million in the previous year[42] - The ending balance of cash and cash equivalents was approximately $4.257 billion, up from $2.430 billion year-over-year[42] Other Financial Metrics - The company had a weighted average return on equity of 1.12%, an increase of 0.32 percentage points compared to the previous year[10] - The company reported non-recurring gains of ¥7,268,962.93 for the period, primarily from government subsidies and fair value changes of financial assets[11] - The company reported a foreign exchange gain of CNY 5,148,193.06 in Q1 2024, compared to a gain of CNY 1,404,636.26 in Q1 2023, reflecting a significant increase[37] - The company plans to implement new accounting standards starting in 2024, which may affect financial reporting[42] Employee Compensation - The company reported a decrease in employee compensation payable to CNY 137,614,069.98 from CNY 197,926,244.94, a reduction of approximately 30.50%[25] - The company has seen a reduction in cash payments for operating activities, including a decrease in payments to employees from $197 million to $163 million[39]